COMPARATIVE ANALYSIS OF COST AND RESOURCE USE AMONG PATIENTS WITH BRAIN METASTASIS BY INITIAL PRIMARY CANCER

Author(s)

Ganguli A1, DaCosta Byfield S2, Teitelbaum A3, Ray S11Abbott Laboratories, Abbott Park, IL, USA, 2OptumInsight, Eden Prairie, MN, USA, 3i3 Innovus, Eden Prairie, MN, USA

OBJECTIVES: To examine variation in real world health care utilization (HCU) and costs associated with management of brain metastasis (BrMts) by primary malignancy type.  METHODS: A retrospective analysis utilized claims-data from a national health insurer, identifying patients ≥18 yrs with  ≥2 claims ≥7 days apart for BrMets (ICD-9 198.3x) from  January 2004 to April 2010. The index date was the date of the first BrMets claim.  Continuous enrollment (CE) in the health plan for 6 months before (baseline) and 1 month after (follow-up) index date was required; <1 month follow-up was permitted if due to death. Excluding primary brain tumors, baseline CE data (1993 to the index date) was examined to identify the initial primary malignancy. HCU (inpatient stays, office, outpatient and ER visits) and all-cause per-patient per-month (PPPM) costs were examined. RESULTS: A total of 1031 lung and 395 breast cancer patients, and 93 with melanoma were included.  Baseline Charlson comorbidity score was not significantly different.  Mean age at BrRMets diagnosis was highest for lung (60yr) compared to breast cancer (55yr) and melanoma (56yr)[p-value<0.01].  Rates of HCU (events/person-month) were significantly different for melanoma, breast and lung cancer patients: 0.28 versus 0.17 and 0.24 for inpatient stays; 3.16 versus 3.87 and 3.94 for office visits; 2.84 vs. 2.69 and 2.80 for outpatient visits [p-value<0.01].  Total costs PPPM were highest for melanoma ($21,373) compared to breast ($17,933) and lung cancer ($15,199) [p-value=0.001].  Inpatient costs PPPM represented the largest portion of medical costs (44%-50%), but were not significantly different across cohorts: melanoma ($9397), breast ($8781) and lung cancer ($7628).  Pharmacy costs PPPM were highest among melanoma ($1555) then breast ($737) and lung cancer ($720) [p-value <0.001]. CONCLUSIONS: Variation was observed in HCU and costs among BrMets patients based on initial primary tumor type. Analyses of cost studies on BrMets patients need to take this into consideration.

Conference/Value in Health Info

2011-11, ISPOR Europe 2011, Madrid, Spain

Value in Health, Vol. 14, No. 7 (November 2011)

Code

PCN30

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×